CapsoVision, Inc. (CV)
CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening
CapsoVision NASDAQ: CV outlined its strategy to expand capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening applications, highlighting its artificial intelligence capabilities, cloud-based workflow and upcoming regulatory submissions.
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision Q2 Earnings Call Highlights
CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.
CapsoVision Q1 Earnings Call Highlights
CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
